Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Can an aspirin a day keep atherosclerosis at bay?

04.09.2002


Research yields another benefit to low-dose aspirin

The original miracle drug, aspirin, continues to surprise medical scientists. While studies have proven that aspirin can prevent a second heart attack by thinning the blood, researchers at the University of Pennsylvania School of Medicine have shown that aspirin can also prevent heart attacks and stroke through an entirely different mechanism. Using laboratory models, the Penn researchers demonstrated that aspirin also lessens the inflammation associated with atherosclerosis and stabilizes athersclerotic plaque. Their findings are presented in the current issue of Circulation. "The past decade has seen a lot of research indicating that atherosclerosis is a chronic inflammatory disease," said Domenico Praticò, MD, assistant professor in Penn’s Department of Pharmacology. "Our findings show that aspirin not only decreases inflammation in the arteries and the growth of the atherosclerotic plaque, but it also beneficially alters the consistency of the plaque that remains."

Atherosclerosis, also known as hardening of the arteries, is a main cause of heart attacks and strokes, two leading causes of death in the United States. A variety of factors, including genetics and diet, spur the disease, which occurs as cholesterol-rich cells of the immune system accumulate inside of blood vessels. As these plaques grow, they cause the blood vessels to narrow. If a portion of the plaque breaks off it can induce the formation of a thrombus, a blood clot that could completely obstruct blood flow and cause a heart attack. Likewise, a portion of the thrombus could also travel through the bloodstream to the brain, where it could cause a stroke.



The Penn researchers found that low-dose aspirin leads to a change in the composition of the plaque, turning it from a soft foamy material to a harder material that is less likely to rupture.

"After aspirin, we find more collagen and smooth muscle cells in arterial plaque and significantly less cholesterol-rich cells," said Praticò. "Of course, it is better to have no plaque at all, but if you have plaque in your arteries, you would prefer it to stay put – where it will do the least harm."

Although the exact causes of atherosclerosis are unclear, researchers have known that the inflammation found in atherosclerosis is associated with increased levels of cellular inflammatory signals called cytokines. Plaque formation is also associated with increased levels in the aorta of a protein called NF-?B that controls the formation of these cytokines, stimulates the growth of immune cells and the accumulation of low-density lipoproteins (LDL) – also known as the ’bad’ cholesterol. The Penn researchers have found that aspirin lowers the amount of both cytokines in the blood stream and the NF-?B in the aorta, suggesting a potent anti-inflammatory action of the drug.

Praticò and his colleagues hypothesize that these novel effects of low-dose of aspirin are independent from its known function as blood thinner.

Aspirin directly inhibits the cycloxygenase (COX) enzyme, which allows platelets in the blood to form clots. After aspirin blocks COX, it enables this enzyme to produce powerful anti-inflammatory molecules such as lipoxins, which in turn could inhibit the formation of cytokines – the very molecules that may stimulate atherosclerosis.

While Praticò recognizes more research needs to be done, aspirin could provide a potent, and inexpensive way to fight atherosclerosis. Low-dose aspirin has already been proven effective in preventing a second heart attack. There is a danger, however, taking large doses of aspirin, which can lead to gastrointestinal bleeding.

So, what constitutes a low-dose?

"Generally, we consider between 80mg and 250mg of aspirin to be ’low-dosages’ – about the amount you would find in children’s aspirin," said Praticò. "Of course, anyone considering taking a regimen of low-dose aspirin should consult a physician first." The research detailed in this study was supported by grants from the American Heart Association and the National Institutes of Health.

Greg Lester | EurekAlert

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>